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Abstract The Cancer Vaccine Consortium of the Sabin
Vaccine Institute (CVC/SVI) is conducting an ongoing
large-scale immune monitoring harmonization program
through its members and aYliated associations. This eVort
was brought to life as an external validation program by
conducting an international Elispot proWciency panel with
36 laboratories in 2005, and was followed by a second
panel with 29 participating laboratories in 2006 allowing
for application of learnings from the Wrst panel. Critical
protocol choices, as well as standardization and validation
practices among laboratories were assessed through
detailed surveys. Although panel participants had to follow
general guidelines in order to allow comparison of results,
each laboratory was able to use its own protocols, materials
and reagents. The second panel recorded an overall signiW-
cantly improved performance, as measured by the ability to
detect all predeWned responses correctly. Protocol choices
and laboratory practices, which can have a dramatic eVect
on the overall assay outcome, were identiWed and lead to
the following recommendations: (A) Establish a laboratory
SOP for Elispot testing procedures including (A1) a count-
ing method for apoptotic cells for determining adequate cell
dilution for plating, and (A2) overnight rest of cells prior to
plating and incubation, (B) Use only pre-tested serum
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304 Cancer Immunol Immunother (2008) 57:303–315optimized for low background: high signal ratio, (C) Establish
a laboratory SOP for plate reading including (C1) human
auditing during the reading process and (C2) adequate
adjustments for technical artifacts, and (D) Only allow
trained personnel, which is certiWed per laboratory SOPs
to conduct assays. Recommendations described under (A)
were found to make a statistically signiWcant diVerence in
assay performance, while the remaining recommendations
are based on practical experiences conWrmed by the panel
results, which could not be statistically tested. These results
provide initial harmonization guidelines to optimize Elispot
assay performance to the immunotherapy community. Fur-
ther optimization is in process with ongoing panels.
Keywords Elispot · ProWciency panel · Validation · 
Harmonization · Immune monitoring
Abbreviations
CVC/SVI Cancer Vaccine Consortium of the Sabin 
Vaccine Institute
PBMC Peripheral blood mononuclear cells
CEF Cytomegalie, Epstein Barr, and influenza virus
CMV Cytomegalie virus
NIAID National Institute of Allergy and Infectious
Diseases
CV CoeYcient of variation
SOP Standard operating procedure
Introduction
Elispot is a widely used assay for immune monitoring pur-
poses [6, 17, 25, 39]. Measuring immune responses has
been accepted as an important endpoint in early clinical
trial settings in order to prioritize further vaccine or other
immunotherapy development [11, 22, 24, 26, 38]. Despite
the overwhelming use of various immune assays for exactly
that purpose, reported results are often met with skepticism,
caused mainly by two reasons: (1) high variability among
results from the same laboratories and/or among diVerent
laboratories, and (2) the lack of demand to report standardi-
zation, validation and training strategies as well as assay
acceptance criteria by the laboratories conducting immune
testing. This is surprising since the reporting of results for
other clinical endpoints, e.g., side eVects, has to follow
strict guidelines and deWnitions.
The Clinical Laboratory Standard Institute (CLSI)
clearly phrased the demand for internal validation of
immune assays as well as external validation in proWciency
panels [28]. ProWciency panels are a common strategy for
clinical laboratories to prove their ability to perform clini-
cal tests at a level that permits patient testing. DeWned as a
program in which multiple specimens are periodically sent
to laboratories for analysis, and in which each laboratory’s
results are compared with those of the other laboratories
and/or with an assigned value [27], proWciency panels serve
various purposes:
1. To provide regulatory and sponsoring agencies with
conWdence that reported data are generated following
necessary standards and rigor that supports product
licensure.
2. To provide an external validation tool for individual
labs.
3. To provide proof to patients and volunteers that neces-
sary measures have been taken to allow successful
study participation [3].
Some reports about comparison of Elispot performances
among laboratories have been published [5, 32, 33]. A two-
step approach to assay harmonization is being described by
the C-IMT monitoring panel in this issue [2]. The earliest
report, a four-center comparative trial in 2000, showed that
most participants were able to correctly detect low fre-
quency responses or absence of response against speciWc
peptides in PBMCs from six donors, following their own
protocol [33]. Another four-center comparison was con-
ducted among members of the Elispot standardization
group of the ANRS in France [32]. This study demon-
strated overall good qualitative and quantitative agreement
in Elispot results in the participating labs when testing HIV
negative and positive donors for reactivity against a variety
of peptides. All labs used their own protocol, but shared a
high level of Elispot experience. An important program was
launched by the NIAID for 11 international laboratories
participating in HIV-1 clinical trials [5]. The panel demon-
strated good concordance in qualitative detection of spe-
ciWc immune responses in previously deWned and tested
donors, but also notable inter-laboratory and intra-sample
variability in spot counts, cell recovery and viability. This
observation was met with strict standardization strategies
across all panel members, and the panel was repeated twice
with all laboratories following a standardized protocol.
Variability was decreased under these conditions, but not
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Cancer Immunol Immunother (2008) 57:303–315 305abrogated (Cox, personal communication). JustiWcation for
the strict standardization approach among participating
HIV vaccine laboratories can be found in the nature of HIV
vaccine testing programs. Immune monitoring for these
vaccine trials is performed at many sites simultaneously.
Further, results from diVerent trials need to be comparable
in order to identify most suitable vaccine candidates.
Importantly, the experimental Elispot setup is similar or
identical in most laboratories, where PBMCs are tested
against a variety of peptides [25, 31].
In contrast, immune monitoring approaches in the cancer
vaccine Weld are more heterogeneous, based on the vast
variety of vaccine design, type of cancer, and availability of
antigen presenting cells. Standardization of the entire Eli-
spot protocol across laboratories is therefore not feasible.
We set out to devise a strategy to identify issues and deW-
ciencies in current Elispot practices, and to identify com-
mon sources of assay variability within and between
laboratories, with the extended goal of standardizing the
identiWed factors in an assay harmonization eVort across
laboratories.
In 2005, the Cancer CVC/SVI initiated an Elispot proW-
ciency panel program to achieve this goal. In addition to
oVering an external validation program, the CVC addressed
the need for such strategy by comparing assay performance
across the Weld, identifying critical protocol choices and
gaining an overview of training and validation practices
among participating laboratories.
For this program, predeWned PBMCs from four donors
with diVerent ranges of reactivity against two peptide pools
were sent to participants for Elispot testing. Laboratories
had to further provide cell recovery and viability data, as
well as respond to surveys describing their protocol choices
and training and validation status.
In response to the survey results, the CVC/SVI estab-
lished requirements for laboratories to participate in
future proWciency panels, which included the existence
of a Standard Operating Procedure (SOP) prior to joining
the program. Further, individualized assay performance
assessment was oVered to all laboratories, together with
suggestions for implementation of protocol optimization
steps.
The results of the second Elispot proWciency panel con-
ducted a year later demonstrated a signiWcant improvement.
The results and survey data allowed the identiWcation of
critical protocol choices for a successful assay performance
(Fig. 1).
Materials and methods
Participants and organizational setup
All participants were members of the Cancer Vaccine Con-
sortium or its aYliated institutions, the Ludwig Institute for
Cancer Research (LICR) and the Association for Immuno-
therapy of Cancer (C-IMT). Laboratories were located in
ten countries (Australia, Belgium, Canada, Germany, Italy,
Japan, France, Switzerland, UK, and USA). Each labora-
tory received an individual lab ID number. Panel leadership
was provided by a scientiWc leader experienced in Elispot,
in collaboration with the CVC Executive oYce. SeraCare
BioServices, Gaithersburg, MD, served as central labora-
tory, providing cells, pretesting and shipping services, as
well as logistical services like blinding of panelists. IDs
were not revealed to panel leader, CVC or statistician dur-
ing the panel.
Thirty-six laboratories including the central lab partici-
pated in panel 1, 29 including the central lab in panel 2.
Twenty-three laboratories participated in both panels. Six
new panelists were added to the second testing round.
Thirteen dropped out after the Wrst panel. Main reasons
for drop out were switch of assay priorities and not meet-
ing criteria for panel participation. Various groups stated
that one time participation fulWlled their need for external
validation.
Fig. 1 Initial guidelines for har-
monization of the Elispot assay 
to optimize assay performance 
and reproducibility derived from 
two international proWciency 
panels, based on their Wndings 
and trends observed
Initial Elispot Harmonization Guidelines to Optimize Assay Performance
A Establish laboratory SOP for Elispot testing procedures, including: 
A1 Counting method for apoptotic cells for determining adequate cell dilution for 
plating
A2 Overnight rest of cells prior to plating and incubation 
B Use only pre-tested and optimized serum allowing for low background  : high signal ratio 
C Establish SOP for plate reading, including:
C1 Human auditing during reading process 
C2 Adequate adjustments for technical artifacts
D Only allow trained personnel, which is certified per laboratory SOP, to conduct assays 123
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PBMCs from healthy donors were obtained from a com-
mercial donor bank, manufactured and processed under
GMP conditions using established Standard Operating Pro-
cedures at SeraCare. PBMCs were frozen using a rate con-
trolled freezer and transferred to the vapor phase of liquid
nitrogen. A three lot validation study was performed [20] in
which the following was validated: cell separation proce-
dure, freezing media, dispensing eVect on function, freez-
ing procedure, and shipping on dry ice. It was demonstrated
that functionality and viability were maintained throughout
the procedure. In addition, Elispot values from fresh and
frozen PBMCs, shipped on dry ice, were nearly equivalent.
Each vial of PBMCs contained enough cells to ensure a
recovery of 10 million cells or more under Seracare’s SOP.
PBMCs were pretested at the central laboratory for reac-
tivity against the CEF [7] and CMV pp65 peptide pools
[23]. The CEF peptide pool was obtained through the NIH
AIDS Research and Reference Reagent Program, Division
of AIDS, NIAID, NIH. It contains 32 8-11mers known to
elicit CD8-restricted responses, and serves as a widely used
control in IFN Elispot assays [7]. The CMV pp65 peptide
pool was a generous gift of the NIAID and Becton Dicken-
son. This pool consists of 135 15mers overlapping by 11
amino acids, and has been shown to elicit CD8- and CD4-
restricted responses [23]. PBMCs were selected for no, low,
medium and strong responses against both peptide pools,
and repeatedly Elispot-tested at Seracare in order to conWrm
responder status. Response deWnition was set arbitrarily
for the spot number/well (200,000 PBMC): no responder:
average median/panel 1 + 2 = 1 (CMV and CEF); low
responder: average median/panel 1 + 2 = 18 (CMV) and 40
(CEF); medium responder: average median/panel 1 + 2 = 98
(CMV) and 127 (CEF); and high responder: average median/
panel 1 + 2 = 396 (CMV) and 398 (CEF).
Peptide pools were resuspended in DMSO and further
diluted with PBS to a Wnal concentration of 20 g/ml.
Aliquots of 150 l of peptide pool were prepared for Wnal
shipment to participants. Corresponding PBS/DMSO aliqu-
ots for medium controls were also prepared. Participants
were blinded to the content of these vials, which were
labeled as “Reagent 1, 2 or 3”.
All cells and reagents sent to participants in both panels
were obtained from the same batches.
Cells and reagent vials were shipped to all participants
for overnight delivery on suYcient dry ice for 48 h. Ship-
ping was performed by Seracare under their existing SOPs.
Elispot
Participants received a plate layout template and instruc-
tions for a direct IFN Elispot assay which had to be
performed in one Elispot plate. Each donor was tested in
six replicates against three reagents (medium, CEF and
CMV peptide pool). Further, 24 wells were tested for the
occurrence of false positive spots by the addition of T cell
medium only. About 200,000 PBMC/well were tested
against 1 g/ml peptide pool or the equivalent amount of
PBS/DMSO. All other protocol choices were left to the par-
ticipants, including choices about: Elispot plate, antibodies,
spot development, use of DNAse, resting of cells, T cell
serum, cell counting and spot counting method. All plates
were reevaluated at ZellNet Consulting (Fort Lee, NJ) with
a KS Elispot system (Carl Zeiss, Thornwood, NY), soft-
ware KS Elispot 4.7 (panel 1) and KS Elispot 4.9 (panel 2)
in blinded fashion. Each well in each plate was audited.
Since the focus of this study was on assay performance
and protocol evaluation and not on the deWnition of a posi-
tive response, we prospectively deWned the ability to detect
a response (independent of magnitude) by using the follow-
ing “empirical” method: the antigen-speciWc spot counts
per 2 £ 105 PBMCs had to be >10, and at least 3£ as high
as the background reactivity. Similar approaches have been
described elsewhere [5, 8].
Statistical analysis
The following parameters were calculated for the overall
panel and the individual participant’s performance, using
either lab-speciWc counts or central recounts: the mean,
standard deviation, and coeYcient of variation (CV), the
median, minimum, and maximum spot counts for each
donor and reagent and the media only wells. Box plots were
used to illustrate the distribution of spot counts across the
panel per given test condition. Further, individual results
were represented as box plots comparing lab counts with
recounts, central lab results and overall panel results. For
panel 2, results from repeating laboratories were also com-
pared in box plot format for each donor and condition. The
Fisher’s Exact test was used to compare the proportions of
laboratories which missed to detect responses in each panel.
For the comparison of recovery and viability, the Student’s
t test was applied.
Results
Feasibility
In the Wrst proWciency panel, shipping and Elispot testing
among 36 laboratories from 9 countries were conducted
without delays. The success of this panel demonstrates the
feasibility of such large international studies, the biggest of
such format as of today, under the described organizational
setup. The second panel with 29 participating laboratories123
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ever, customs delays of dry ice shipments to some inter-
national sites required repeated shipments of cells and
antigens to these destinations. Based on this experience,
the use of dryshippers with liquid nitrogen is being imple-
mented for international destinations in the third CVC
panel round in 2007.
Recovery and viability of PBMCs in panel 1 and 2
Participants were asked to record recovery and viability of
cells immediately after thawing (Table 1). The mean and
median for both parameters were almost identical in both
panels, and for all four donors (mean cell recovery between
11.5 and 13.3 million cells and mean viability between 85
and 91%). Only a small percentage of laboratories recov-
ered less than 8 million cells (13% in panel 1 and 14% in
panel 2). The percentage of groups reporting less than 70%
viability was 7% for both panels.
Interestingly, only 4/10 laboratories in panel 1, and 4/7
laboratories in panel 2 with recoveries below 8 million cells
were from international locations. Similar, only 1/5 labora-
tories in panel 1 and 2/5 in panel 2 reporting viabilities less
than 70% belonged to international sites. This clearly dem-
onstrates that location for dry ice shipment had no eVect on
overall cell recovery and viability.
We also investigated whether low (<8 million) or very
high (>20 million) cell recovery had an inXuence on spot
counts, assuming that these were potential erroneous cell
counts, leading to too low or too high cell dilutions, respec-
tively, what in turn would lead to too high (in case of
underestimating cell number) or too low (in case of overes-
timating cell number) spots counts. However, except for a
few sporadic incidents, there was no correlation between
cell counts and spot counts (data not shown) in either direc-
tion. Only one laboratory with low recovery and low viabil-
ity was found to have peptide pool-speciWc spot counts for
all donors much below the panel median.
The use of an automated cell counter (Guava) did not
reveal any trend in recovery for this group (recovery ranged
from 6.7 to 25.1 million cells), nor a diVerence compared to
the overall panel recovery data. In contrast, the mean cell
viability per donor measured by Guava counter users was
signiWcantly lower than the overall cell viability in users of
a hemocytometer (P < 0.01, see table in Fig. 5).
Elispot results in panel 1
All 36 laboratories completed testing of all 4 donors against
medium, CEF and CMV peptide pool. Spot appearance and
size as well as occurrence of artifacts diVered dramatically
among laboratories (not shown). Four outlier laboratories
were identiWed, which detected less than half of the
responses correctly. In all four cases, detected responses
were well below the panel median, and often, there was high
background reactivity (up to 270 spots/well) in medium
controls. No obvious protocol choices could be identiWed
which could have been responsible for the suboptimal per-
formance. One out of the four laboratories had little experi-
ence at the date of the panel. Another group reported a less
experienced scientist performing the assay. A third outlier
repeated the assay, and was able to perform adequately. No
feed back was available from the fourth group.
Thirty-two out of 36 labs were able to detect medium
and strong responders as well as the non-responder. How-
ever, almost 50% of participants were challenged with the
detection of the low responder. The responses measured for
that particular donor (mean spot counts/well for CEF = 42
and for CMV = 22) has been chosen for illustration pur-
poses. Figure 2 demonstrates the distribution of responses
measured including intra-laboratory variability for this
donor against all three reagents and across both panels.
In panel 1, 17 labs did not detect the response against the
CMV peptide pool. In one case, the response was missed
due to high reactivity against medium. Three other labs
missed to detect the response due to inaccurate spot counting,
Table 1 Cell recovery and viability in both proWciency panels
a PBMCs from same donors and batches were used in both panels
b P1/P2 refer to data from panel 1 (P1) and panel 2 (P2)
Donora Mean P1/P2b Median P1/P2 Minimum P1/P2 Maximum P1/P2
Cell recovery in 106 cells 1 12.5/11.5 12.0/12.0 6.8/1.0 26.4/18.8
2 13.3/12.3 13.2/12.6 5.5/0.3 28.4/22.4
3 13.1/12.8 13.6/12.8 6.7/1.7 25.1/24.3
4 12.8/12.4 11.9/12.9 5.6/6.2 34.4/22.7
Viability (%) 1 88/85 89/89 48/58 100/98
2 87/88 89/90 57/67 100/98
3 91/87 93/90 54/69 100/100
4 86/89 90/92 43/75 100/98123
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erroneously included in counts (Fig. 3). Reevaluation of
those plates revealed that those labs had spot counts indi-
cating a response against CMV.
A similar scenario was found for response detection
against the CEF peptide pool. Thirteen laboratories missed
to detect the response, one of which due to high reactivity
against medium, and one due to inaccurate spot counting.
An interesting observation was that 23 groups reported
false positive spots in a range of 1–26 spots/well. Reevalua-
tion revealed that the actual number of groups with false
positive spots was lower (12), and the false positive spot
number range per well fell between 0 and 8.
Survey results about protocol
During the Wrst panel, participants had to provide informa-
tion about their protocol choices: plates, potential prewett-
ing of PVDF, antibodies, enzyme, substrate, use of DNAse
during PBMC thawing, resting of cells, serum used, cell
Fig. 2 Laboratory spot counts and variability for low responder across
panel participants. Panel 1 left column, panel 2 right column. The re-
agent tested is indicated. Lab-speciWc spot counts per 200,000 cells are
depicted as box plots with the box presenting the interquartile range,
the triangle the mean and the horizontal line the median. Maximum
and minimum spot counts are illustrated through the upper and lower
mark. The horizontal line across a graph demonstrates the overall panel
median. The central laboratory performed the assay under two diVerent
conditions in panel 1. Results from both experiments are presented;
therefore 37 laboratories for panel 1. Laboratory ID numbers do not
correlate in both panels. In panel 1, laboratory #18 reported spot counts
for the medium control as high as 270 per well (mean 81, median 34.5).
For proper illustration of all other panel data, these data were omitted
from the graph. Intra-laboratory variability and variability among par-
ticipants as well as reactivity against medium are representative for all
responder PBMCs tested123
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protocol choices across the panel participants. The most
common choices for the parameters listed above were as
follows: use of PVDF plates (64%) prewetted with Ethanol
(52%), coated with Mabtech antibodies (67%) at 0.5–
0.75 g/well (33%); spot development with HRP (53%)
from Vector Laboratories (33%) using AEC (44%) from
Sigma (42%); no use of DNAse when thawing cells (83%),
and no resting period for cells prior to the assay (53%); use
of human serum (64%); cell counting with trypan blue
exclusion using a hemocytometer (78%); and plate evalua-
tion with a Zeiss reader (36%).
There were some clear trends for international sites with
preferred use of the AP/BCIP/NBT development system
(83 via 29% in the US), the use of nitrocellulose plates (75
via 21% in the US), and the use of Mabtech antibodies (83
via 58% in the US). On the other hand, 7/8 laboratories
using an automated cell counter were located in the US.
We stratiWed our panel participants into groups consist-
ing of: (1) outliers (failed to detect more than 50% of
responses correctly), (2) labs which missed weak response
detection only, and (3) labs with correct qualitative
response detection in all four donors. We then checked for
speciWc parameters that could be potentially responsible for
the groups’ panel performance. We were not able to detect
any parameter that seemed to be responsible for missed
response detection. In contrast, laboratories with the same
overall protocol choices (except serum) could have very
diVerent assay performance, whereas laboratories with
diVerent protocol choices could have almost identical spot
counts (Fig. 4). Reasons for the failure to detect protocol
choices which signiWcantly proved the advantage or disad-
vantage of their use can be found in (1) the study design
with open protocol choices allowing participants to follow
their own SOP, (2) the overall wide range in choices
of reagents and materials (e.g., 7 diVerent sources for the
coating antibody with 10 diVerent total antibody amounts
reportedly used, 10 diVerent enzyme sources, 7 diVerent
Elispot reader systems, cell resting times between 0.5 and
20 h, serum choices unique for each laboratory etc.), and
(3) the small sample sizes resulting from this dispersion of
protocol choices. These widely spread individual protocol
choices among participants did not allow the aggregation of
data for an adequately powered statistical analysis.
One trend observed was that the users of an automated
cell counter (7 labs used a Guava cell counter) had an over-
all better assay performance (Fig. 5), with no outliers in this
group and only two laboratories who missed to detect the
weak responders (29 vs. 52% in non-Guava users).
Almost half of the participants (47%) introduced a rest-
ing period for cells before adding them to the Elispot plate.
The time frame varied from 0.5 to 20 h. A valuable side-by-
side comparison was performed by the central laboratory,
in which two tests were run in parallel using the lab’s SOP
with the exception that their standard resting period of 20 h
was replaced by a shorter resting period of 2 h in the second
test. The results are summarized in Fig. 6, demonstrating a
signiWcant increase in spot numbers for all peptide pool-
speciWc responders when cells were rested for 20 h, without
an increase in background reactivity (P < 0.05 for the weak
responder against CMV; for all other antigen-speciWc
responses in all donors P < 0.01).
Survey results about validation and training practices
During the lively discussion of the results of panel 1 and its
protocol survey at the Annual CVC meeting in Alexandria
in November 2005, it was suggested that the level of expe-
rience, standardization and validation of participating labo-
ratories might have been the cause for the variability and
performances observed. In response, we conducted a sur-
vey among panelists, in which 30 laboratories participated.
As expected, the experience and Elispot usage varied sig-
niWcantly. Some laboratories had the Elispot assay estab-
lished less than one year before panel testing, whereas
others used the assay for more than 10 years. The experience
Fig. 3 Elispot assay results can 
be confounded by plate evalua-
tion accuracy. The table demon-
strates spot counts for PBMC/
medium control wells with many 
artifacts from three diVerent 
laboratories (Lab X, Y, Z). 
Respective well images are 
shown below each column for 
that speciWc group. DiVerences 
in lab-speciWc spot counts 
(“own”) and counts from 
reevaluation in an independent 
laboratory (“central”) including 
resulting variability measures 
are presented in the table
Spot Counts
Lab X 
Own           Central 
Lab Y 
Own           Central 
Lab Z 
Own             Central 
Mean 81.5            3.3 16.7            4.8 9.7                1.7 
SD 104.7          1.8 25.9            2.9 5.3                1.6 
Median 34.5            3.5 6                 5.5 10                 1.5 
Minimum 3                 1 3                 1 2                   0 
Maximum 270             6 69               9 18                 4 
Lab-specific images of wells with erroneous evaluation by participant123
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widely.
Interestingly, even though 2/3 of participants reported to
have speciWc training guidelines for new Elispot performers
in place, more than 50% never or rarely checked on the
scientist’s performance after the initial training.
Almost all laboratories indicated that they use an SOP
that had been at least partially qualiWed and/or validated.
Validation tools and strategies varied widely. Only 12
groups monitored variability, whereas 23 reported the use
of external controls of some kind (e.g., T cell lines,
predeWned PBMC, parallel tetramer testing).
Thirteen groups were found to have some kind of criteria
implemented for assay acceptance. Among the 20 diVerent
criteria reported, not one was described by more than one
lab.
Mirroring these survey results, 20 laboratories believed
that they need to implement more validation steps. All
except one group expressed their strong interest in pub-
lished guidelines for validation and training strategies for
Elispot.
Elispot results in panel 2
Based on the experience from the Wrst panel, acceptance
criteria for participation in the program were redeWned.
Only laboratories with established SOPs were accepted.
The second panel was repeated with identical experimental
setup as the Wrst panel, and with the same batches of
PBMCs, peptides and control reagents. Twenty-nine labo-
ratories participated including the central lab. This time,
there were no outlier performers identiWed. The number of
groups that did not detect the weak responder dropped dra-
matically (P < 0.01) from 47% (17/36 labs) in panel 1 to
14% (4/29) in panel 2 (Fig. 2). The overall panel median
for the CMV-response in the weak responder increased
from 14 spots in panel 1 to 21 spots in panel 2, and for the
CEF response from 30 to 51, respectively.
Of the 23 labs repeating the panel, 8 had changed their
protocol before panel 2, 3 of which as an immediate
response to results from the Wrst panel. One outlier lab from
panel 1 participated in panel 2, and improved its perfor-
mance by detecting all responses correctly as per reevalua-
tion counts. Only their lab-speciWc evaluation did not detect
the low CMV responder. Overall, 4/23 panel-repeating labs
(17%) did not detect the low CMV-responder, 3 of which
also did not detect this response in panel 1. About 10/23
groups missed the low CMV responder in panel 1, but 7 of
these laboratories were able to detect it in panel 2. Only one
repeater detected the low CMV response in panel 1, but not
panel 2. This is a clear performance improvement for that
group (47% missed this response in panel 1), and highlights
Fig. 4 Demonstration of examples of concordance of spot counts
among three laboratories (Lab I–III) using diVerent Elispot protocols
(a, high responder), or of disagreement of spot counts for two labora-
tories (Lab IV–V) using almost identical protocol choices (b, medium
responder). Lab-speciWc spot counts per 200,000 cells are depicted as
box plots with the box presenting the interquartile range, the triangle
the mean and the horizontal line the median. Maximum and minimum
spot counts are illustrated through the upper and lower mark. The tri-
angle refers to the overall panel mean for that speciWc condition. Re-
sults of Lab I–III are shown in a, and results of IV–V in b. The table
contains reference to the Wgure above, and information about speciWc
protocol choices
A
Lab I 
(A: blue, open)
Lab II 
(A: red, solid) 
Lab III 
(A: green, open)
Lab IV 
(B: blue open 
Lab V 
(B: red solid) 
Plate type PVDF MCE PVDF MCE MCE
Antibodies Mabtech Mabtech Own kit Mabtech Mabtech
Development HRP/AEC AP/BCIP-NBT HRP/AEC HRP/AEC HRP/AEC
Serum Human AB FCS FBS Human AB AIM-V
DNase No Yes Yes No No
Resting No Yes-Overnight Yes-Overnight No No
Cell counting Hemocytometer Hemocytometer Automated Hemocytometer Hemocytometer
Reader Zeiss AID CTL Zeiss Zeiss
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Cancer Immunol Immunother (2008) 57:303–315 311the usefulness of multiple participation in panel testing as
an external training program.
We ran an in-depth analysis of the results and previous
survey responses, where available, from participants who
missed the weak responder, as well as from laboratories
with marginal detection of response, including personal
communication. We were able to narrow down the possible
sources for these performances. Two laboratories missed
responses due to inaccurate evaluation, during which they
either included artifacts into spot counts or simply did not
count the majority of true spots, as central reevaluation
revealed. One laboratory did not follow the assay guide-
lines. The majority of laboratories, however, followed com-
mon protocol choices, but had either very low response
detection across all donors and antigens, or detected very
high background reactivity in some or all donors. This pat-
tern pointed to serum as the possible cause for suppressed
reactivity or non-speciWc stimulation. Three of these labo-
ratories shared with the CVC that retesting their serum
choice indicated that they had worked with a suboptimal
serum during the panel; and that they now successfully
introduced a diVerent serum/medium to their protocol with
improved spot counts. Serum choices included human AB
serum, FCS, FBS, and various serum-free media. There
was no diVerence in assay performance detectable between
these groups.
Discussion
The CVC conducted two large international Elispot proW-
ciency panels in which participants tested four batches of
predeWned donor PBMC for CEF and CMV peptide pool
reactivity. Common guidelines like number of cells per
well and amount of antigen had to be followed, in order to
allow result comparison and reduce variability due to the
known inXuence of cell numbers plated [2, 14]. A surpris-
ing Wnding from the Wrst panel was that almost half of
the participants were not able to detect the weak responder.
The initial protocol survey did not allow the detection of
common sources for this sub-optimal performance. In some
cases, laboratories with identical protocol choices
performed very diVerently, whereas others with distinct
protocols had almost identical spot counts (Fig. 4). This
Fig. 5 Distribution of mean 
spot counts (upper two graphs) 
and cell viability (table) among 
the users of a Guava automated 
cell counter (a) and users of a 
hemocytometer (b). Spot counts 
per well (200,000 cells) are 
represented on a logarithmic 
scale. D1–4 refer to the donor 
tested with D1 being the strong, 
D2 the low, D3 the medium and 
D4 the non-responder. The 
tested reagent is indicated (med 
medium). The mean viability per 
donor reported by Guava users 
and users of other cell counting 
methods (one lab used an 
automated cell counter from 
Beckman Coulter, all others 
used a hemocytometer with 
trypan blue exclusion) is 
presented in the table below the 
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Mean cell viability
Guava users Non-Guava users 
Donor 1 80.8 86.7
Donor 2 78.4 85.6
Donor 3 84.0 89.8
Donor 4 79.2 85.5123
312 Cancer Immunol Immunother (2008) 57:303–315observation supports the premise that many common Eli-
spot materials and reagents (e.g., plates, antibodies, spot
development reagents) perform equally or similarly well;
and that there are other factors which inXuence the outcome
of the Elispot assay.
Various laboratories missed the response detection by
inaccurately evaluating their Elispot plate, independent of
the reader used, as reevaluation revealed (Fig. 3). This
observation is in contrast to results from the Wrst NIAID
proWciency panel, which describes good agreement in spot
counts from participants and experienced, independent cen-
ters [5]. Operator-dependent variability in Elispot evalua-
tion results is a known phenomenon [15]. Despite the
availability of high resolution readers and software features
for automated spot gating and other potentially helpful
options, it is essential to employ well trained operators for
spot counting, to audit all plates, and to implement changes
of reading parameter in cases when well and spot appear-
ances diVer from the overall assay, typically for technical
reasons. For that, SOPs used for plate evaluation might
require revision. The use of available certiWcation and train-
ing services can be helpful.
Cell counting is a protocol step known for introducing
variability. Because of the wide range in PBMC recovery,
we investigated whether cell counts could have been poten-
tially erroneous, which would lead to wrong Wnal cell dilu-
tions, and can therefore lead to too high or low spot counts.
Despite large diVerences in cell recovery (from 5.5 to
34.4 million cells per vial in panel 1), we did not Wnd a cor-
relation between cell recovery and spot counts. Very low
(<8 million) and very high (>20 million) cell counts were
consistently found for all donors among the same few labo-
ratories. Both, hemocytometers and automated counters
were used in those laboratories. Various automated cell
counters have been introduced to the market, which do not
only oVer automated spot counting features, but also the
discrimination of apoptotic, viable and dead cells. The use
of such systems can potentially decrease variability in cell
counts, and most importantly increase the accuracy of via-
ble cell counts [4, 21]. Seven laboratories in panel 1 used
the Guava counter, which allows the discrimination of
apoptotic cells. Even though our panel did not reveal a
diVerence in cell counts between Guava and hemocytome-
ter users, it could be demonstrated that the overall cell via-
bility reported by Guava users was signiWcantly lower. This
could likely be attributed to the ability to discriminate
apoptotic cells with this method. Smith et al. [35] recently
reported the usefulness of apoptosis acceptance criteria that
allowed the separation of PBMC samples by their ability to
respond to an antigenic stimulus or not.
The introduction of a resting period for thawed cells is
known to be advantageous since apoptotic cells die during
the resting period, and Wnal dilutions for the assay are based
on a more homogenous population of viable cells [16, 18].
In contrast, the addition of a mixture of viable and apopto-
tic cells, which are prone to die during assay incubation
time, directly after thawing leads to lower spot counts. Dur-
ing panel 1, the central laboratory performed a side-by-side
comparison of the inXuence of a 2 and 20 h resting period
on Wnal spot counts, and demonstrated that a 20 h resting
period yielded signiWcantly higher counts (Fig. 6). ProW-
ciency testing results from the C-IMT also support the
introduction of a cell resting period for Elispot assays [2].
Even though almost half of participants in panel 1 let cells
rest before addition to the plate, there was no clear correla-
tion to the magnitude of peptide-speciWc spot counts. This
might have been due to the variation of resting times
between 0.5 and 20 h, and other protocol variables, which
included the actual resting protocol. Factors like serum and
serum concentration, cell concentration, and actual storage
condition (e.g., tissue culture Xasks or plates can lead to
cell adherence and therefore loss of professional antigen-
presenting cells) are known to inXuence the success of cell
resting.
There are no scientiWc studies published about the eVect
of serum choices on immune assay results, one of the best
known “secrets” in immunology [16]. It is critical to choose
serum that supports low background reactivity, but strong
signals. The leading choice in this panel to use human AB
serum reXects the historic preference for human immune
assays. Each serum batch, however, is unique in its ability
to support optimal assay resolution, and may potentially
contain mitogenic or immune suppressive factors. There
Fig. 6 Comparison of the eVect of 2 h (checkered bars) and 20 h (solid
bars) resting periods for cells after thawing, before adding to the assay.
D1–4 CEF/CMV refer to the speciWc donor and peptide pool tested.
Background reactivity for all donors and testing conditions was
between 0 and 5 spots (not shown). The standard error is shown.
* Indicates a statistical signiWcant diVerence of P < 0.01 in spot counts
between 2 and 20 h resting periods for a given donor and reagent; #
indicates in statistical diVerence with P < 0.05 (Student’s t test)
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Cancer Immunol Immunother (2008) 57:303–315 313was some anecdotal evidence that the serum choice among
our panelists was responsible for suboptimal performance.
Interestingly, six laboratories preferred to work with serum-
free medium. None of these groups observed high back-
ground reactivity, but two failed to detect the weak
responder.
A survey conducted among participating laboratories
shed light on validation and training practices. The wide
experience range of participating laboratories, in combina-
tion with various levels and approaches to validation and
training, correlated with the overall high variability in panel
results. In response, new criteria for panel participation
were introduced for panel 2. The outlier lab number
decreased from 4 to 0 in the new panel, however 3/4
outliers from panel 1 did not participate in panel 2. The
percentage of laboratories that did not detect the weak
responder decreased signiWcantly from 47 to 14% (P < 0.01).
This improvement might have been partially due to the
stricter participant selection in panel 2. However, 7/10 labs
repeating the panel improved their performance by
correctly detecting the low CMV responder in panel 2,
while missed in panel 1. A striking Wnding was that 2/3
of all laboratories stated that they believed they needed to
implement more validation. And all but one group
expressed their wish for published guidelines for Elispot
assay validation and training.
The outcomes from these two proWciency panels Wrst
provide Initial Elispot Harmonization Guidelines for Opti-
mizing Assay Performance (Fig. 1) that can fulWll this need
and may provide—if implemented widely—the grounds for
substantial improvement of assay utility for research appli-
cations and development of immune therapies. This can be
implemented in accordance with assay recommendations
made for cancer immunotherapy clinical trials by the Can-
cer Vaccine Clinical Trial Working Group [12]. Further
optimization is aimed for through ongoing proWciency
panel work conducted by the CVC.
Validation of assays is now a requirement for all end-
point parameters in clinical trials [30]. There are an increas-
ing number of publications available describing validated
Elispot assays [1, 19, 25, 34]. These papers contain valu-
able scientiWc information, but only limited referral to FDA
regulations. The FDA guidelines for validation of analytical
procedures [9] describe validation as the process of deter-
mining the suitability of a given methodology for providing
useful analytical data, which consists of analyzing or veri-
fying the eight or nine assay parameters as described in the
US pharmacopeia or the ICH guidelines [13, 37]. Only few
publications address validation of bioassays and Elispot in
FDA terms [10, 16, 29, 36]. And even these few publica-
tions give only limited advice on how to validate the Eli-
spot assay in a given laboratory setting, not to mention
speciWc training guidelines.
Furthermore, acceptance criteria for assay perfor-
mance were only used by a limited number of laborato-
ries, and each criterion was unique for the laboratory that
used it.
These observations should be a wake-up call for the
immune monitoring community, which does not only
include the cancer vaccine Weld, but also the infectious
disease and autoimmunity Weld and others. General assay
practices for the detection of antigen-speciWc T cells are
comparable across all Welds. The CVC as part of the
Sabin Vaccine Institute is intending to develop and
tighten collaborations with groups from other research
and vaccine development areas. Published documents
with speciWc criteria for Elispot assay validation, assay
acceptance criteria and training guidelines will be most
valuable for the immune monitoring Weld, and are now
being established as CVC guidelines as a result of the
described studies. Continuous external validation pro-
grams need to be a part of these eVorts in order to check
upon the success of inter-laboratory harmonization
including assay optimization, standardization and valida-
tion as well as of laboratory-speciWc implementation of
guidelines and protocol recommendations. These eVorts
are essential to establish the Elispot assay and other
immune assays as standard monitoring tools for clinical
trials.
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Appendix: CVC Elispot proWciency panel members  
(in alphabetical order)
Richard Anderson, Oxxon Therapeutics Ltd, Oxford,
UK
Nadege Bercovici, IDM S.A., Paris, France
Jean Boyer, University of Pennsylvania, Philadelphia,
PA
Cedrik Britten, Johann-Gutenberg University Mainz,
Germany
Dirk Brockstedt, Cerus Corporation, Concord, CA
Judy Caterini, sanoW pasteur, Toronto, Canada
Vincenco Cerundolo, Ludwig Institute for Cancer
Research, Weatherall Institute of Molecular Medicine,
Oxford, UK
Weisan Chen, Ludwig Institute for Cancer Research,
Heidelberg, Australia
Timothy Clay, Duke University Medical Center, Dur-
ham, NC
Robert Darnell, Rockefeller University, New York, NY
Sheri Dubey, Merck & Co, Inc., West Point, PA123
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Sacha Gnjatic, Ludwig Institute for Cancer Research,
Memorial Sloan-Kettering Cancer Center, New York,
NY
Richard Harrop, Oxford BioMedica, Oxford, UK
Don Healey, Argos Therapeutics, Inc., Durham, NC
Alan Houghton, Memorial Sloan-Kettering Cancer
Center, New York, NY
Elke Jaeger, Ludwig Institute for Cancer Research,
Krankenhaus Nordwest, Frankfurt, Germany
William Janssen, H Lee MoYtt Cancer Center, Univer-
sity of South Florida, Tampa, FL
Lori Jones, Dendreon Corporation, Seattle, WA
W. Martin Kast, Norris Comprehensive Cancer Center,
USC, Los Angeles CA
Julia Kaufman, Rockefeller University, New York, NY
Alexander Knuth, Ludwig Institute for Cancer
Research, University Hospital Zürich, Zürich, Switzer-
land
Abdo Konur, Johann-Gutenberg University Mainz,
Germany
Ferdynand Kos, Johns Hopkins University School of
Medicine, Baltimore, MD
Odunsi Kunle, Ludwig Institute for Cancer Research,
Roswell Park Cancer Institute, BuValo, NY
Kelledy Manson, Therion Biologics Corporation, Cam-
bridge, MA
Mark Matijevic, MGI Pharma Biologicals, Lexington,
MA
Yoshishiro Miyahara, Ludwig Institute for Cancer
Research, Mie University Graduate School of Medi-
cine, Mie, Japan
Cristina Musselli, Antigenics, Inc., Lexington, MA
Walter Olson, University of Virginia Health System,
Charlottesville, VA
Dennis Panicali, Therion Biologics Corporation, Cam-
bridge, MA
Shreemanta Parida, Max-Planck Institute for Infection
Biology, Berlin, Germany
Joanne Parker, Globeimmune Inc., Louisville, CO
Heike Pohla, Ludwig-Maximilians University, Mün-
chen, Germany
Michael Pride, Wyeth Pharmaceuticals, Pearl River,
NY
Ruth Rappaport, Wyeth Pharmaceuticals, Pearl River,
NY
Philip Reay, Biovex, Abingdon, UK
Licia Rivoltini, Istituto Nazionale Tumori, Milano,
Italy
Pedro Romero, Ludwig Institute for Cancer Research,
Hospital Orthopedique, Lausanne, Switzerland
Patric Schiltz, Hoag Cancer Center, Newport Beach,
CA
Hiroshi Shiku, Ludwig Institute for Cancer Research,
Mie University Graduate School of Medicine, Mie,
Japan
Craig SlingluV, University of Virginia Health System,
Charlottesville, VA
Jacqueline Smith, Dartmouth Medical College, Leba-
non, NH
Daniel Speiser, Ludwig Institute for Cancer Research,
Hospital Orthopedique, Lausanne, Switzerland
Diane Swanlund, Biomira Inc., Edmonton, Canada
Michael Vajdy, Chiron Corporation, Emeryville, CA
Annegret Van der Aa, Innogenetics NV, Ghent, Bel-
gium
JeVrey Weber, Norris Comprehensive Cancer Center,
USC, Los Angeles CA
Thomas Woelfel, Johann-Gutenberg University Mainz,
Germany
Jedd Wolchok, Memorial Sloan-Kettering Cancer
Center, New York, NY
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